Africa: Generic HIV Prevention Injection Moves Closer to 120 Countries After FDA Approval
[Capital FM] Nairobi -- Access to a twice-yearly HIV prevention injection is moving closer to millions of people in low- and middle-income countries after Dr. Reddy's Laboratories secured tentative approval from the United States Food and Drug Administration (FDA) for the first generic version of lenacapavir.
The Food and Drug Administration (FDA) has given provisional approval for a generic version of a groundbreaking HIV prevention medicine, potentially expanding access to lower- and middle-income countries. The drug, created by Dr. Reddy’s Laboratories, is expected to roll out next month as part of a collaborative initiative driven by several global health organizations.
The annual cost per patient will be $40, which is comparable to the cost of daily oral medication. The injectable drug, termed lenacapavir, is considered a game-changer in the fight against HIV due to its nearly complete protection against the virus with just one injection every six months. The brand-name counterpart, Yetzugo, is marketed by Gilead Sciences and received FDA approval in the previous year.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Generic HIV prevention injection moves closer to 120 countries after FDA approval capitalfm.africa
- STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries statnews.com
- Generic lenacapavir HIV prevention shot wins US FDA approval iol.co.za
- US approves cheap generic of breakthrough HIV shot for poorer countries medicalxpress.com
- U.S. approval of cheap, generic HIV prevention shot may boost global rollout science.org
